The real cons of Mounjaro — and how to weigh them up

Step 1, understand which side effects are common, and why they happen

The most consistent downside of Mounjaro is its gastrointestinal profile. Nausea tops the list; vomiting, diarrhoea, constipation, reflux and burping follow. These happen because tirzepatide slows how quickly the stomach empties, which is part of how it reduces appetite, but that same mechanism can make the first weeks of treatment uncomfortable. The NHS tirzepatide patient page lists these as common effects, meaning they affect roughly one in ten people or more.

Most people find the discomfort is worst after a dose increase and eases within a week or two as the body adjusts. It rarely disappears entirely, but it does tend to become manageable. The titration schedule (starting at 2.5 mg for four weeks before any increase) exists largely for this reason, and if you are curious about where that opening dose sits relative to lower experimental amounts, our guide explains what is considered a microdose of tirzepatide and how it differs from the licensed starting point. Headache, fatigue and dizziness are also reported, though less often.

One serious but infrequent risk deserves a clear mention. In January 2026, the MHRA issued a Drug Safety Update on GLP-1 medicines and acute pancreatitis, confirming it as a known risk requiring urgent medical attention if severe, persistent abdominal pain appears, especially pain that radiates to the back. If that happens, stop and call 111 or go to A&E, it does not resolve itself.

Step 2, know who Mounjaro is not suitable for

Not everyone who wants Mounjaro can take it, and that is a genuine drawback for some people. The licence excludes anyone who is pregnant, breastfeeding, or actively trying to conceive. Under-18s are also outside the licensed indication. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 rules it out altogether, as do certain serious gastrointestinal conditions and a history of pancreatitis, all of which require a prescriber's assessment.

The oral contraceptive interaction is worth flagging separately because it catches people off guard. UK guidance is clear: if you take the pill, you need to add a non-oral contraceptive method for the first four weeks of Mounjaro treatment and for four weeks after every dose increase. Absorption of hormones from oral medication can be reduced during those windows. Transdermal HRT users are advised to discuss the same issue with their doctor. None of this makes Mounjaro unsuitable for most people, but it does mean starting it is not as simple as just beginning a new pen. This is one of the reasons a consultation genuinely matters, rather than being a formality, and it also explains why anyone considering getting Mounjaro without a consultation should understand the risks that approach carries. You can read more about what a Mounjaro consultation covers to understand how these factors are assessed.

Step 3, factor in the practical and financial realities

Mounjaro is not cheap, and that is worth saying plainly. Eli Lilly raised UK list prices on 1 September 2025; reported private prices since then range roughly £149–£375 per month depending on dose and provider. The higher doses (where the greatest weight-loss results tend to appear in trials) sit at the upper end of that range. A full course of treatment to reach and maintain the top dose runs to several months, sometimes more than a year.

For a broader look at what those monthly costs tend to include and exclude, the Mounjaro pricing guide breaks this down by dose and what legitimate services should cover. Headline prices from some providers exclude the consultation, the prescription and aftercare, so the comparison is not always straightforward. At nume (at nume) one transparent price covers consultation, prescription, medicine and next-working-day tracked delivery. But cost is still a real con for many people, and it is worth budgeting honestly before committing.

The titration schedule also means patience is part of the deal. Most people do not see significant results for the first eight to twelve weeks. The 12-week mark, roughly when someone might reach the 7.5 mg dose, is when many report the clearest change. Expecting fast results from the opening pens sets people up for disappointment. And if treatment is stopped, appetite typically returns over weeks to months as the medicine clears the system. The NICE technology appraisal TA1026 recommends reviewing continuation if less than 5% weight loss has occurred after six months at the highest tolerated dose, a realistic checkpoint that some people do not pass.

Step 4, put the cons in context before deciding

The cons of Mounjaro are real. So are the results: in SURMOUNT-1, thousands of adults with obesity achieved an average weight reduction of around 20–21% at the highest dose over 72 weeks, a scale of change that other medicines have not matched in head-to-head comparisons. Whether that trade-off makes sense depends on your health history, your other medications and your goals. That is a clinical judgement, not a Google search.

If you want the fuller picture (benefits alongside the drawbacks) the pros and cons of Mounjaro page covers both sides in detail. For anyone who has been researching tirzepatide more broadly, our Mounjaro overview sets out the pharmacology and licensing context without the brand lens. And if you are weighing up treatment options more generally, speaking to our prescribers is the best way to get an honest view of whether Mounjaro fits your situation or whether something else makes more sense.